School of Medicine
Showing 541-560 of 2,425 Results
-
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
On Leave from 07/01/2025 To 06/30/2026Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
David Epstein
Clinical Assistant Professor, Medicine - Infectious Diseases
Current Research and Scholarly Interestspulmonary infections, bronchiectasis, and suppurative lung diseases complicating BMT and CAR-T; bronchiectasis; NTM infections
-
Berrin Er
Affiliate, Medicine - Med/Pulmonary, Allergy & Critical Care Medicine
Visiting Scholar, Medicine - Med/Pulmonary, Allergy & Critical Care MedicineBioBerrin Er, M.D., is a physician and visiting scholar in the Division of Pulmonary, Allergy, and Critical Care Medicine. She graduated from Istanbul University Faculty of Medicine and completed her residency training as well as a critical care fellowship at Hacettepe University, Ankara, Turkey.
As a visiting researcher, Dr. Er integrates her clinical expertise with advanced computational methods. Her research focuses on interstitial lung diseases, with an emphasis on radiomics, and on analyzing diverse datasets related to respiratory diseases using data-driven approaches. Her work aims to enhance disease characterization and support clinical decision-making.
www.linkedin.com/in/berrin-er-b3214999 -
Arvin Eslami
Research Associate, Medicine - Med/Immunology & Rheumatology
Current Role at StanfordResearch Associate in the Division of Immunology & Rheumatology at Stanford University School of Medicine.
Responsibilities include supporting immunotherapy and cellular therapy research (CAR-T and TIL), clinical data organization, database management, and contribution to manuscripts, systematic reviews, and meta-analyses.
July 2025 – Present -
Ali Etemadi
Postdoctoral Scholar, Nephrology
Current Research and Scholarly InterestsI am a clinician and data scientist focusing on drawing causal inferences from observational data when randomized controlled trials are not feasible. Currently, my work centers on patients with late-stage chronic kidney disease, a rapidly growing population for which evidence is limited due to their frequent exclusion from RCTs. At the moment, I aim to move towards precision medicine approaches to optimize outcomes for these patients.
-
Markus Eyting
Postdoctoral Fellow, Medicine - Primary Care and Population Health
BioI am an applied microeconomist, using experimental methods as well as survey and administrative data to study the interplay of beliefs and individual decision-making with applications to health, discrimination, and machine learning.
For more information, please visit my website: https://meyting.com/. -
Robert Michael Fairchild
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDr. Fairchild’s research focuses on musculoskeletal and organ-based ultrasound in rheumatic disease, including arthritis, calcinosis, vascular pathology, and interstitial lung disease. He develops ultrasound-based outcome measures and leads projects applying deep learning and explainable AI to imaging. He also performs ultrasound-guided synovial biopsies to support translational and clinical research.
-
Bita Fakhri, MD, MPH
Associate Professor of Medicine (Hematology)
BioDr. Bita Fakhri is an Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, Richter’s syndrome, and other hematologic malignancies.
As a clinical scientist, Dr. Fakhri is dedicated to patient care, trainee education, and the development of novel therapies for individuals with CLL/SLL. She has co-authored numerous publications focusing on CLL, targeted therapies, and cellular therapies in hematologic malignancies.
Dr. Fakhri currently serves as Director of the CLL Clinical Trial Portfolio at Stanford. In addition, she is actively involved in building infrastructure to expand access to clinical trials and promote equity in care for underserved and marginalized populations across the Stanford catchment area. -
Titilola Falasinnu
Assistant Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)
BioI am primarily a lupus researcher and identify as a pain scientist and methodologist in this field. Systemic lupus erythematosus (SLE) disproportionately affects women and racial minorities and is the fifth most common cause of death among 15- to 24-year-old Black and Hispanic women in the U.S., highlighting its significant public health impact. More than half of patients with SLE experience chronic pain, often secondary to SLE itself or overlapping conditions (e.g., migraines, low back pain, fibromyalgia), contributing significantly to disability and impaired quality of life. Chronic pain is not merely a symptom but a disease in its own right—one that deserves the same rigorous study and clinical attention as comorbidities like kidney disease and cardiovascular disease in rheumatology. The enormous global burden of chronic pain underscores the urgent need for a clear, standardized definition of pain as a disease, particularly in autoimmune rheumatic diseases where pain can arise from inflammatory, nociplastic, and biopsychosocial mechanisms. Without recognizing pain as a distinct disease entity, its mechanisms remain poorly understood, and effective treatment strategies remain underdeveloped.
I am a co-Principal Investigator of the Pain Intelligence Lab, where our mission is to advance the study of pain as a disease in rheumatology through two primary objectives. First, we develop and validate computational methods that enable clinicians and researchers to leverage electronic health records, administrative claims, and disease registries to study chronic pain as a distinct disease entity in rheumatology. By applying machine learning, natural language processing, and real-world data analysis, we seek to enhance pain phenotyping, classify distinct pain subtypes, and develop predictive models for treatment response. Second, we use a biopsychosocial framework to examine the predictive power of biomarkers and psychosocial measures in rheumatologic pain. By integrating biological, psychological, and social determinants of pain, we aim to conduct rigorous, patient-oriented research that translates targeted assessments into mechanistically informed, personalized treatment approaches for optimized clinical care. Ultimately, my long term career goal is to bridge the gap between research and clinical practice, ensuring that pain management in autoimmune rheumatic diseases is precise, equitable, and optimized for improved patient outcomes. -
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
